Specifically, the Mount Sinai study was designed
to test whether pharmacological compounds designed
to block the function of XPO1 / CRM1 could stop disease progression in mouse models that exhibit some of the characteristics of MS. Researchers found that two chemical agents (called KPT - 276 and KPT - 350) prevented XPO1 / CRM1 from shuttling cargo out of the nucleus of
nerve cells, which protected them from free
radicals and structural
damage.